AstraZeneca Taps Source BioScience for Cancer PGx | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Source BioScience said today that it will provide drugmaker AstraZeneca with a companion diagnostic testing service for lung cancer patients in the UK.

The service agreement with AstraZeneca will enable doctors at the National Health Service to identify which lung cancer patients have certain genetic mutations in their tumors that may make them sensitive to tyrosine kinase inhibitor therapies, which in turn may help guide doctors' treatment decisions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.